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at any potential DVT-related clinical event [DRCE]), and
archivist-coded hospitalisation summaries. Utilization
was grouped by resource-type and summed. Stratiﬁed
analyses were performed by age, gender, DVT site (prox-
imal/distal), and patient location (in-patient/out-patient).
RESULTS: At diagnosis, mean age was 57 years, 48%
were male, 1/3 were in-patients and 55% had proximal
DVT. By 4 months, 17% of patients had ≥1 new hospi-
talisation, 24% had been investigated for a DRCE and
there were a mean of 0.9 emergency department visits,
3.4 family physician visits, 5.2 specialist physician visits
and 13.4 episodes of use of paramedical services. Half 
of patients had purchased elastic stockings, and 69%
were still taking warfarin. By 1 month, 31% and 17% of
patients reported cutting down on household and work
activities, respectively; at 4 months, these ﬁgures were
15% and 7%. There was an average loss of 7.3 work-
days during the 4-month period. CONCLUSIONS:
Although usually considered an acute condition, DVT 
is associated with signiﬁcant utilization of resources and
loss of productivity for at least 4 months after diagnosis.
The longterm economic impact of DVT should be further
quantiﬁed and factored into cost-effectiveness studies of
strategies to prevent or treat DVT.
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OBJECTIVE: To generate estimates of the cost-
effectiveness of thromboprophylaxis with enoxaparin
versus no thromboprophylaxis (usual care) in patients
with acute medical illness in the health care setting of
Brazil from the perspective of the public Brazilian health
care system. METHODS: Markov process analysis tech-
niques were used to model the health economic outcomes.
Data on probabilities of clinical events were derived from
clinical trial data from the MEDENOX trial, other pub-
lished literature and OECD (Organisation for Economic
Co-Operation and Development) country-speciﬁc popu-
lation mortality data; units of health care utilization were
derived from the Delphi panels; prices and tariffs were
derived from ofﬁcial lists. RESULTS: Analysis over a 1-
year period showed that the cost per VTE event avoided
was REAL 2349 (US$870; €906) and the cost per life
saved was REAL 8296 (US$3073; €3201), when assum-
ing no higher risk for morbidity and mortality for asymp-
tomatic patients. The lifetime model (again, assuming 
no higher risk for recurrence of VTE for asymptomatic
patients), showed that the use of enoxaparin leads to a
cost per VTE event avoided of REAL 2194 (US$813;
€846) and cost per life year gained of REAL 574
(US$213; €221). The lifetime model, which assumes a
higher risk of VTE recurrence in asymptomatic patients,
leads to a cost of REAL 317 (US$117; €122) per VTE
event avoided and REAL 90 (US$33; €35) per life year
gained. CONCLUSION: The results showed that the
favourable clinical beneﬁt of enoxaparin results in posi-
tive short and long-term health economic beneﬁts.
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OBJECTIVES: While the cost of managing patients with
myocardial infarction has been extensively studied, 
few data are available on the cost of managing unstable
angina (UA) patients. The aim of the study was to assess
the cost of UA patients in six European countries (France,
Belgium, Italy, Spain, Sweden, UK). METHODS: A
cohort simulation model was used. Patients entered the
model when hospitalised for UA. Resources use during
initial hospitalisation (length of stay, invasive procedures)
was extracted from a prospective database. The frequency
and type of following rehospitalisations for cardiovascu-
lar events were derived from a recent clinical trial. The
time horizon was nine months and the perspective was
that of the health care system. The hospital costs used for
each country were based on the local DRG system. Ofﬁ-
cial costs of outpatient medications were used. All costs
are expressed for year 2001. RESULTS: The global cost
of managing UA patients over a nine-month period was
divided in three parts: cost of initial hospitalisation, cost
of subsequent hospitalisations and cost of medications.
Total length of stay of initial hospitalisation ranges from
7.2 days in Sweden to 10.8 days in Spain. The number of
days in intensive care unit ranges from 1.6 in UK to 3.8
in Italy. In France, the global cost was estimated at €7471
per patient, breakdown of cost was as follows: initial hos-
pitalisation (57%), subsequent hospitalisations (33%),
medications (10%). For other countries, the global cost
per patient was as follows: Belgium €6987, UK £3083,
Italy €6908, Spain €6633, Sweden SEK 57608, with a
consistent breakdown across countries. CONCLUSION:
First hospitalisation is the main cost driver. Nevertheless
the cost of subsequent hospitalisations accounts for about
one third of the total cost highlighting the need for pre-
ventive treatment of subsequent cardiovascular events in
UA patients.
